Sitagliptin Associated with Increase in Heart Failure Hospitalizations — Physician’s First Watch
Sitagliptin Associated with Increase in Heart Failure Hospitalizations
By Larry Husten
Use of the diabetes drug sitagliptin (Januvia) appears to be associated with increased risk for heart failure hospitalization among patients with preexisting heart failure, according to an observational study in JACC: Heart Failure.
Researchers analyzed insurance claims for over 7600 patients with diabetes and heart failure. People who used the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin were not more likely than nonusers to have a primary endpoint event (death or all-cause hospitalization). However, they were more likely to be hospitalized for heart failure (12.5% vs. 9.0%).
The authors say their finding "is likely clinically relevant" and might have an impact on the choice of add-on therapy for heart failure patients with diabetes. An editorialist writes that the results "add to a small but growing body of evidence that suggests DPP-4 inhibitors as a class of drugs, and possibly diabetes drugs in general, may increase the risk of heart failure." However, he notes, the "increase in absolute risk, if present at all, appears to be small."
Adapted from CardioExchange.